Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
Maria Elena Lunati, Vincenzo Cimino, Davide Paolo Bernasconi, et al.
Pharmacological Research (2023) Vol. 199, pp. 107040-107040
Open Access | Times Cited: 10

Showing 10 citing articles:

Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study
Mar Garcia-Zamora, Gemma García‐Lluch, Lucrecia Moreno, et al.
Pharmacological Research (2024) Vol. 206, pp. 107295-107295
Open Access | Times Cited: 13
Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
Yan Tian, Chenxia Zhou, Qun Yan, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access | Times Cited: 1
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network
Mahmoud Nassar, Omar Nassar, Hazem Abosheaishaa, et al.
Journal of Endocrinological Investigation (2024)
Closed Access | Times Cited: 6
The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review
Stanislaus Ivanovich Krishnanda, Marie Christabelle, Oliver Emmanuel Yausep, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2239-2239
Open Access
Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE -2 study
Cesare Berra, Roberto Manfrini, Francesco Bifari, et al.
Pharmacological Research (2024) Vol. 210, pp. 107517-107517
Open Access | Times Cited: 3
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique
Carlos Augusto Yepes, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, et al.
Diabetes Therapy (2025)
Open Access
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Roberta Manti, Salvatore De Cosmo, Paolo Desenzani, et al.
Diabetes Therapy (2025)
Open Access
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents
K. Malas, Salman Kazmi, Yu Mi Kang, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis
Yuna Chae, Sun‐Hong Kwon, Jin Hyun Nam, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 8, pp. 721-729
Closed Access | Times Cited: 1
Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 9, pp. 1202-1210
Open Access | Times Cited: 1
Page 1

Scroll to top